Sovereign Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.18M Buy
981
+44
+5% +$45K 0.18% 97
2026
Q1
$862K Buy
937
+137
+17% +$139K 0.15% 131
2025
Q4
$860K Sell
800
-39
-5% -$37.3K 0.15% 130
2025
Q3
$640K Buy
839
+46
+6% +$34.2K 0.12% 155
2025
Q2
$618K Buy
793
+49
+7% +$38.1K 0.13% 145
2025
Q1
$615K Sell
744
-4
-0.5% -$3.33K 0.14% 139
2024
Q4
$578K Buy
748
+65
+10% +$53.8K 0.13% 143
2024
Q3
$605K Buy
683
+25
+4% +$22.5K 0.14% 134
2024
Q2
$596K Sell
658
-13
-2% -$10.4K 0.15% 130
2024
Q1
$522K Buy
671
+59
+10% +$42K 0.14% 146
2023
Q4
$357K Buy
612
+140
+30% +$81.7K 0.11% 170
2023
Q3
$254K Sell
472
-311
-40% -$160K 0.09% 189
2023
Q2
$367K Buy
+783
New +$328K 0.12% 166

Other funds holding LLY

Sovereign Financial Group's LLY Position: Q2 2026 in Review

Sovereign Financial Group increased its Eli Lilly (LLY) stake by 4.7% in Q2 2026, buying an estimated $45K and bringing the position to 981 shares worth $1.18M. The position accounts for 0.18% of the portfolio, ranked #97.

Sovereign Financial Group first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sovereign Financial Group held 981 shares of Eli Lilly worth $1.18M as of Q2 2026.
  • Sovereign Financial Group bought 44 Eli Lilly shares in Q2 2026, an estimated $45K.
  • Eli Lilly made up 0.18% of Sovereign Financial Group's portfolio in Q2 2026, its #97 holding.
  • Sovereign Financial Group first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sovereign Financial Group's 13F filing for Q2 2026, filed 24 Jul 2026.